Artículo Aceptado para su pre-publicación / Article Accepted for pre-publication

Titulo / Title:
Biodisponibilidad de dos formulaciones de fentanilo oral transmucosa en voluntarios sanos: un estudio abierto, cruzado y aleatorio / Bioavailability of two oral fentanyl transmucosal formulations in healthy volunteers: and open-label, crossover, randomised study

Autores / Authors:
BELEN SADABA DIAZ DE RADA, Almudena Gómez-Guiu Hormigos, Pere Roset Arissó, José Ramón Azanza Perea, Beatriz Goñi Allo

DOI: 10.20986/resed.2018.3678/2018

Instrucciones de citación para el artículo / Citation instructions for the article:
SADABA DIAZ DE RADA BELEN, Gómez-Guiu Hormigos Almudena, Roset Arissó Pere, Azanza Perea José Ramón, Goñi Allo Beatriz . Biodisponibilidad de dos formulaciones de fentanilo oral transmucosa en voluntarios sanos: un estudio abierto, cruzado y aleatorio / Bioavailability of two oral fentanyl transmucosal formulations in healthy volunteers: and open-label, crossover, randomised study. Rev. Soc. Esp. Dolor. 2018. doi: 10.20986/resed.2018.3678/2018.

Este es un archivo PDF de un manuscrito inédito que ha sido aceptado para su publicación en la Revista de la Sociedad Española del Dolor. Como un servicio a nuestros clientes estamos proporcionando esta primera versión del manuscrito en estado de pre-publicación. El manuscrito será sometido a la corrección de estilo final, composición y revisión de la prueba resultante antes de que se publique en su forma final. Tenga en cuenta que durante el proceso de producción se pueden dar errores lo que podría...
afectar el contenido final. El copyright y todos los derechos legales que se aplican al artículo pertenecen a la Revista de la Sociedad Española de Dolor.
BIOAVAILABILITY OF TWO ORAL FENTANYL TRANSMUCOSAL FORMULATIONS IN HEALTHY VOLUNTEERS: AN OPEN-LABEL, CROSSOVER, RANDOMISED STUDY

BODISPONIBILIDAD DE DOS FORMULACIONES DE FENTANILÓ ORAL TRANSMUCOSA EN VOLUNTARIOS SANOS: UN ESTUDIO ABIERTO, CRUZADO Y ALEATORIZADO

B. Sádaba Díaz de Rada¹, A. Gómez-Guiu Hormigós¹, P. Nolasc Roset Arissó², José Ramón Azanza Perea¹, Beatriz Goñi Allo³

¹Unidad de Investigación Clínica. Clínica Universitaria de Navarra. Pamplona, Navarra. ²Departamento Médico. Ferrer. Barcelona. ³Geiser Pharma, S.L. Mutilva, Navarra. España

CORRESPONDENCE:
Belén Sádaba Díaz de Rada
bsadaba@unav.es

Received 13-04-2018
Accepted 16-04-2018

ABSTRACT

Introduction: Oral transmucosal fentanyl citrate (OTFC) was the first product specifically designed for the treatment of breakthrough pain. It is formulated as a sweetened lozenge on a plastic handle (stick) and it is self-administered by the patient, allowing the modulability or flexibility in dosing.

Objectives: To prove bioequivalence of a test (T) OTFC product compared to the reference (R) formulation.

Material and methods: Open-label, crossover, randomized, single-dose bioequivalence study in healthy volunteers, with two study periods and two sequences, with a washout period of at least 10 days. On each study day, subjects received 400 μg of fentanyl. They were instructed to rub the tablet gently against the buccal mucosa and
not to suck on or chew it, and the investigators controlled each administration to ensure that it was consumed during 15 minutes. Given the high pharmacokinetic variability, a two-stage design was established and bioequivalence decision was based on 94.12% confidence intervals of $C_{\text{max}}$ and $\text{AUC}_{0-t}$ geometric means ratio.

**Results:** 36 subjects completed the study according to the protocol. Mean $C_{\text{max}}$ were similar with both formulations (814.78 pg/ml for T and 781.83 pg/ml for R) and were attained at the same time (40 min. for T and 50 min. for R), and their bioavailability was also very close ($\text{AUC}_{0-t}$: 3920.12 pg.h/ml for T and 3679.39 pg.h/ml for R). Bioequivalence was confirmed for the two primary parameters, $C_{\text{max}}$ and $\text{AUC}_{0-t}$. No period or sequence effects were observed in any parameter. As bioequivalence was proved in the first phase of the study, it was not necessary to proceed to the second stage. The estimated intraindividual variability was 24.66% and 19.01%, respectively for T and R formulations. Both formulations were well tolerated; 15 mild adverse events were reported.

**Discussion:** The test OTFC product is bioequivalent to the reference one and therefore interchangeable when used clinically. OTFC administration provides faster fentanyl absorption than enteral route and the rate of absorption can be modulated by the administration technique, providing a unique flexibility among all breakthrough pain treatments. The results showed a fast time to maximum concentrations (tmax), in accordance with those originally reported for the reference product, probably favoured by the strict administration technique. Proper patient education is essential to optimize the use of OTFC, as well-trained patients can take advantage of its flexibility to self-controlling pain relief.

**Keywords:** Bioequivalence, breakthrough pain, fentanyl, oral transmucosal fentanyl citrate.

**RESUMEN**

**Introducción:** El citrato de fentanilo oral transmucosa (CFOT) fue el primer medicamento diseñado específicamente para tratar el dolor irruptivo. Está formulado...
como una matriz de polvo comprimido con aplicador de plástico (palito), y el paciente se lo administra, lo que proporciona modulabilidad o flexibilidad de dosis.

**Objetivos:** Probar la bioequivalencia entre el medicamento CFOT test (T) y el de referencia (R).

**Material y métodos:** Estudio abierto, cruzado, aleatorizado, de bioequivalencia a dosis única en voluntarios sanos, con dos periodos y dos secuencias, y con un tiempo de lavado de al menos 10 días. Los sujetos tomaron 400 μg de fentanilo cada día de estudio. Se les instruyó para que restregaran el comprimido contra la mucosa bucal sin chuparlo ni masticarlo, y los investigadores controlaron cada administración para asegurar que se consumía en 15 minutos. Se estableció un diseño en dos etapas por la alta variabilidad farmacocinética esperada, y la decisión de bioequivalencia se basó en los intervalos de confianza al 94,12 % de la razón de las medias geométricas de la $C_{\text{max}}$ y el $\text{AUC}_{0-t}$.

**Resultados:** 36 sujetos completaron el estudio de acuerdo con el protocolo. Las medias de $C_{\text{max}}$ fueron similares con ambas formulaciones (814,78 pg/ml para T y 781,83 pg/ml para R) y se alcanzaron al mismo tiempo (40 min para T y 50 min para R), y su biodisponibilidad también fue muy semejante ($\text{AUC}_{0-t}$: 3920,12 pg.h/ml para T y 3679,39 pg.h/ml para R). Se confirmó la bioequivalencia para los dos parámetros principales, $C_{\text{max}}$ y $\text{AUC}_{0-t}$. No se observaron efecto periodo ni secuencia para ningún parámetro. Como se probó la bioequivalencia en la primera fase del estudio no fue necesario proceder a la segunda fase. La variabilidad intraindividual estimada fue 24,66 y 19,01 %, respectivamente para T y R. Los dos medicamentos fueron bien tolerados; se registraron 5 acontecimientos adversos de intensidad leve.

**Conclusiones:** La formulación CFOT test es bioequivalente con la de referencia, y por tanto son clínicamente intercambiables. La administración de CFOT proporciona una absorción más rápida de fentanilo que la vía enteral y la tasa de absorción puede modularse con la técnica de administración, aportando una flexibilidad única al resto de tratamientos del dolor irruptivo. Los resultados muestran un breve tiempo hasta concentraciones plasmáticas máximas ($t_{\text{max}}$), coincidente con el descrito originalmente para la formulación de referencia, favorecido probablemente por la estricta técnica de administración. Es esencial una adecuada formación de los pacientes para optimizar el
uso de CFOT, ya que los pacientes bien entrenados pueden sacar buen provecho de su flexibilidad para auto-regularse el alivio del dolor.

**Palabras clave:** Bioequivalencia, dolor irruptivo, fentanilo, citrato de fentanilo oral transmucosa.

**INTRODUCTION**

Breakthrough pain is a transitory flare of pain that occurs on a background of relatively well controlled baseline pain and is highly prevalent among patients with cancer. Breakthrough cancer pain (BTCP) shows high inter- and intraindividual variability in rate of onset, maximum intensity, time to maximum intensity and duration (1-3). Opioids are the mainstay of cancer pain pharmacological treatment, but oral opioids can poorly adapt to the rapid onset and short duration of BTCP, which prompted the development of new products that could fit better with this specific time-course of effects, optimizing the balance between pain relief and side-effects (3-5).

Oral transmucosal fentanyl citrate (OTFC), a formulation of fentanyl citrate embedded in a sweetened lozenge on a plastic handle (stick), was the first product specifically designed for the treatment of BTCP. Oral transmucosal absorption of fentanyl provides with greater and faster bioavailability than enteral formulations, thus allowing a faster pain relief (4-6).

Since its approval, several other oral or nasal transmucosal absorption formulations have been approved. They show some differences in their pharmacokinetic profile, and some recommendations point to selecting the product that best matches with the individual characteristics of each patient and pain episode. OTFC owes a characteristic unique among all fentanyl transmucosal products: it is self-administered through a dynamic process that the patient can control to achieve the desired effects, interrupting the administration if pain relief or side-effects occur. This unique feature is termed modulability, flexibility or self-control (2,4,7).

The present study aimed at proving bioequivalence of a test OTFC product compared to the reference formulation.
METHODS

A phase 1, open-label, crossover, single-dose bioequivalence study with two study periods and two sequences comparing the bioavailability of 2 OTFC formulations was conducted at the Clínica Universidad de Navarra Clinical Research Unit in accordance with the “Note for Guidance on Good Clinical Practice” (CPMP/ICH/135/95) (8), the “Guidelines of the Investigation of Bioequivalence” (CPMP/EWP/QWP/1401/98 Rev. 1) (9), and the Declaration of Helsinki (revision, Seoul, 2008). The protocol was approved by the Independent Ethics Committee of Navarre and the volunteers signed their written consent before participating.

Subjects

Participants have to be healthy volunteers of both sexes, aged between 18 and 45 years old, non-smokers, with a body mass index between 19 and 29 kg/m², and with an oxygen saturation equal to or greater than 95 %. Each volunteer underwent an anamnesia, a physical examination, an ECG and analysis before being included in the study to rule out any type of disease.

Design

The duration of the study was 59 days, divided into three phases. During the first phase (screening phase, 21 days), the suitability of the volunteers was evaluated according to the inclusion and exclusion criteria and they underwent a medicinal product administration training process in order to achieve a technique the most accurate and homogeneous possible in all participants. The second phase (intervention phase) involved the two treatment periods, separated by a washout period of at least 10 days, during which the volunteer received, while fasting and at random, one of two formulations: 400 μg of fentanyl Geiser Pharma (test) or Actiq 400 μg (reference, Cephalon UK Ltd.). Holding the product by its handle, volunteers had to place the
fentanyl tablet in their mouth onto the interior side of the cheek and rub it gently against the buccal mucosa, moving it around and rotating the tablet, in order to maximize the mucosal exposure of fentanyl. They were also reminded that they should neither suck on nor chew the tablet. The investigators controlled each administration to homogenize it in all subjects, ensuring that it was consumed during 15 minutes as indicated in the Summary of Product Characteristics for the product (10). Beforehand, and to prevent adverse reactions of fentanyl (especially respiratory depression), 50 mg of naltrexone antidote was administered 12 hours prior, immediately after taking fentanyl, and 12 hours afterwards. After the administration of the drug, blood draws were taken at the following times: 0, 5, 10, 15, 20, 30, 40, 50 minutes and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours, to determine the pharmacokinetic parameters studied. The safety evaluation was carried out with the measurement of blood pressure (BP), heart rate (HR), respiratory rate (RR), temperature (T) and O₂ saturation prior to administration of the drug and at 15, 20, 30, 40, 50 minutes and at 1, 1.5, 2, 2.5, 3, 4 and 8 hours. They were also asked about the onset of adverse events (AEs) after each blood draw. The volunteers remained in hospital from 12 hours before until 12 hours after the administration of the drug. The final phase (follow-up) was conducted during the week posterior to the administration of the second drug dose. It consisted of a physical examination (weight, RR, T, BP, HR and pulse oximetry), a 12-lead ECG and a complete blood test.

Given the variability of the pharmacokinetic parameters described in the literature with this formulation (5), a two-stage design was established allowing a sample size reestimation for a second stage based on the variance estimated from the first stage, if necessary (9). In the first one, 36 subjects were initially included and a first analysis was performed with the data obtained, in such a way that if it was concluded that both formulations were BE, the study would be stopped; otherwise, the intraindividual variability observed would be used for the definitive calculation of volunteers for the second stage, which would be at least 12 more volunteers.

Pharmacokinetic analysis
The determination of fentanyl in plasma was performed by high-performance liquid chromatography with mass spectrometry/(HPLC/MS/MS) using a validated method. The linear relationship between the detector response and the plasma fentanyl concentrations was checked throughout the range of concentrations between 20-5,000 pg/ml. Sample handling included blood draw with a tube with a EDTA K2 anticoagulant, centrifugation at 3,000 rpm at 4 °C for 10 minutes and subsequent freezing at -35 °C for the first 24 hours and at -80 °C the following hours, until transferred to the analytical laboratory.

The following pharmacokinetic parameters of fentanyl were calculated in each subject after the administration of each formulation: C<sub>max</sub>, AUC<sub>0-t</sub>, AUC<sub>0-∞</sub>, t<sub>max</sub> and t<sub>1/2</sub>. The AUC was calculated using the linear trapezoidal method. For the bioequivalence study between the two formulations, the C<sub>max</sub> and AUC<sub>0-1</sub> parameters were compared after their logarithmic transformation and the parametric symmetric confidence intervals (CI) of 94.12 % were defined for each value, according to the rules established for two step designs in the Guidelines of the Investigation of Bioequivalence stated by the European Medicines Agency (9). To calculate the limits of this interval, a 3-way repeated measure ANOVA was applied: formulation (2 categories), sequence (2 categories) and administration period (2 categories). The two treatments were considered bioequivalent if the CI limits calculated fell within the acceptance range of 0.8-1.25 (9).

The safety variables were analysed using Student’s t-test for paired data or ANOVA according to each case. If the conditions for carrying out these tests were not met, the corresponding parametric tests were performed (Wilcoxon, Friedman).

RESULTS

A total of 37 volunteers were included (19 men and 18 women; mean age: 22.7 ± 4.5 years (range 18-43 years); weight: 68.7 ± 11.7 kg (50-93 kg); height: 1.7 ± 0.1 m (1.6-1.9 m); BMI: 23.3 ± 2.3 kg/m<sup>2</sup> (19-29 kg/m<sup>2</sup>), of which 36 completed the study according to the protocol. The mean consumption time of the reference drug was 14 ± 3 minutes (range: 9-23 minutes), and that of the test drug was 15 ± 3 minutes (10-23
Pharmacokinetic parameters

The plasma concentration of the fentanyl formulations after the administration of 400 μg is shown in Figure 1 and the pharmacokinetic parameters ($C_{\text{max}}$, $AUC_{0-t}$, $AUC_{0-\infty}$, $t_{\text{max}}$, and $t_{1/2}$) in Table I. The limits of the confidence interval (94.12 %) of the transformed data from the $C_{\text{max}}$ and $AUC_{0-t}$ of fentanyl parameters fell within the theoretical bioequivalence acceptance interval, therefore both products can be considered bioequivalent (Table II). The analysis of this first stage showed an adequate statistical power to conclude in the acceptance of bioequivalence ($p > 0.97$) with the two evaluated parameters, $C_{\text{max}}$ and $AUC_{0-t}$. The estimated intraindividual variability was 24.66 % and 19.01 %, respectively. This BE was also observed when the calculation was performed based on the classic CIs of 90 %. No period or sequence effects were observed in any parameter. Since this BE was observed in the first phase of the study, it was not necessary to extend the sample with a second stage.

Safety

Both formulations were well tolerated. Overall, 15 adverse events were reported (eight related to the test product and 5 to the reference product), all of which were mild, 7 of these being related to the medication (Table III). All AEs were transient, although rescue medication was required in five cases. In the final check-up, no alterations were observed in any volunteer during the physical examination, ECG or hematological and biochemical test.

DISCUSSION

These results showed that both OTFC formulations are bioequivalent and therefore interchangeable when used clinically. As established in the European guidelines on
bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), a similar clinical effect can be established for both formulations, without the need for the corroborating of a clinical study, as it is commonly accepted that a plasma concentration of a similar active substance is essentially achieved in the same subject in the same time (9). In our case, the geometric mean ratio (test/reference) was consistent with the parameters established in these guidelines to consider both products as BE. In addition, the two formulations presented a similar $t_{\text{max}}$ with a median of 40 minutes in the case of the test formulation and 50 minutes for the reference one, indicating a similar rate of absorption, a fundamental and differentiating aspect in this type of formulation, as BTCP requires rapid onset of pain relief (1-6).

OTFC administration yields plasma concentrations that are higher and more rapidly attained than those after oral administration: fentanyl from OTFC passes partially by mucosal transport directly into the systemic circulation without undergoing enteric absorption and first pass metabolism. In this way, a bioavailability of 50% is achieved, divided equally between fast transmucosal absorption and slower gastrointestinal absorption (5). However, these fractions could variate. Stanley et al. (1989) (11) and Streisand et al. (1991) (12), in the first studies evaluating the absorption and bioavailability of OTFC in adult volunteers, remarked the profound influence oral mucosa absorption plays on the movement of fentanyl into the bloodstream. Indeed, absorption of OTFC trough oral mucosal membranes is complex and involves numerous factors. Thus, the rate of sucking and saliva production (affected by the taste and pH of the lozenge) influences the dissolution process. Moreover, it seems that the amount of saliva immediately swallowed without adequate exposure to mucosal surfaces is a critical factor in overall absorption and probably accounts for much of the inter- and intra-patient variability associated with OTFC delivery. As mentioned in the literature, the coefficient of variation of $\text{AUC}_{\infty}$ and $C_{\text{max}}$ has been established within a range as wide as 7-52 % after the administration of doses from 400–800 μg of OTFC (12-17). Although inter-individual variability can be reduced by the crossover design of most BE studies, the risk of intra-individual variability may persist, especially with this type of formulation (18). According to this high variability, a two-stage crossover bioequivalence (BE) study was chosen as it allows the
reestimation of the second-stage sample size based on the variance estimated from the first-stage results. However, in our case, no extension was required since BE was demonstrated after the analysis of the first 36 subjects. The thorough training during the screening phase and the active supervision of the investigator during the administration of the drug were aimed to reduce the variability in transmucosal absorption, and may have been determinant in decreasing the variance estimated and, therefore, avoiding the second stage of the study. This premise is supported by the fact that the consumption time values for both formulations (mean, maximum and minimum values) were almost identical and in accordance with the approved product label (15 minutes).

As the rate of absorption of fentanyl is highly dependent on the administration technique, OTFC allows the patient to modulate or self-control it to achieve the desired effects, interrupting the administration if pain relief or side-effects occur, providing a flexibility unique among all fentanyl transmucosal products (2,4,5,8).

In the present study, median time to maximum concentrations ($t_{\text{max}}$) was 40-50 minutes for the test and the reference formulations, respectively, which is in accordance with those originally reported for the reference product: 20-62 min (13-17).

Conversely, later studies reported higher figures (90-120 minutes), that indicate a slower rate of absorption (5). These differences put in evidence the influence of the technique of administration on the rate of bioavailability of fentanyl, which is determinant for its pharmacokinetic profile. In fact, the $C_{\text{max}}$/AUC ratios of the reference formulation original studies (weighted mean 0.136; range: 0.10-0.21) are 16 % higher compared to the later studies (weighted mean 0.117; range: 0.09-0.13), which confirms a decrease in fentanyl $C_{\text{max}}$ in the latter. In the present study, $C_{\text{max}}$/AUC ratio resulted in 0.179. Slowing the absorption rate delays the $t_{\text{max}}$, lowers the $C_{\text{max}}$ and causes longer-lasting plasma concentrations, providing a profile of pain relief that could fit better to BTCP episodes with slower onset and longer duration. Proper education of the patient is essential to optimize the use of OTFC (5). Well-trained patients can take advantage of OTFC flexibility or modulability, gaining the empowerment of self-controlling pain relief as Ashburn (1989) reported (7).
Finally, both formulations were well tolerated. The reported adverse events were mild-moderate in intensity and self-limited in most cases. However, the use of naltrexone, an opioid antagonist, could have avoided other serious adverse events opiate-related, as respiratory depression. In any case, it is worth noting that this self-administered formulation, allows the patient to remove the drug immediately if non-tolerated adverse effects appear, unlike other presentations, such as sublingual or intranasal routes (4). This advantage could provide a greater safety in its use. Nevertheless, this action was not required in our study.

In conclusion, our results showed that Fentanyl Geiser Pharma can be considered bioequivalent to the reference product, Actiq. Both will produce the same clinical effect at the same doses within the same safety range, being, therefore, interchangeable. All of this should improve the management of breakthrough pain in oncologic patients by providing an easier access to a medicinal product of proven efficacy and safety in such sensitive condition.

ACKNOWLEDGMENTS

Editorial and medical writing assistance was provided by Dr. José Luis Lorenzo, Ferrer.

CONFLICTS OF INTEREST

This study was sponsored by Geiser Pharma, S.L. The publication was supported by Ferrer.

REFERENCES

1. Gómez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24(1):45-52.
2. Pérez Cajaraville J, Cánovas L, Santos J, Ortega E, Cuello JJ, Alborés R, et al. Variabilidad inter e intraindividual en pacientes con dolor irruptor tratados con
opioïdes. Estudio observacional, prospectivo y multicéntrico. Rev Soc Esp Dolor 2016;23(1):6-15.

3. Rodríguez D, Urrutia G, Escobar Y, Moya J, Murillo M. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. J Pain Palliat Care Pharmacother 2015;29(3):228-46. DOI: 10.3109/15360288.2015.1047554.

4. Mercadante S. Oral transmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Expert Opin Pharmacother 2012;13(6):873-8. DOI: 10.1517/14656566.2012.663353.

5. Moore N, Darwish M, Amores X, Schneid H. A review of the pharmacokinetic profile of transmucosal fentanyl formulations. Curr Med Res Opin 2012;28(11):1781-90. DOI: 10.1185/03007995.2012.735227.

6. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46(4):573-80. DOI: 10.1016/j.jpainsymman.2012.09.009.

7. Ashburn MA, Fine PG, Stanley TH. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report. Anesthesiology 1989;71(4):615-7.

8. Stanley TH, Hague B, Mock DL, Streisand JB, Bubbers S, Dzelzkalns RR, et al. Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. Anesth Analg 1989;69(1):21-7.

9. Good Clinical Practice: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95 - adopted July 96) EudraLex Volume 3C Efficacy 3CC1A. Available at: http://www.efgcp.eu/Downloads/library/3cc1aen.pdf. Last accessed: December 2017.

10. “Note for guidance on the investigation of bioavailability and bioequivalence” CPMP/QWP/EWP/1401/98 Rev. 1/ Corr **. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Last accessed: December 2017.
11. SmPC Abfentiq (Fentanyl Citrate). Proteus Pharma, S.L. Available at: cima.aemps.es. Last accessed: March 2018.

12. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75(2):223-9.

13. Lee M, Kern SE, Kisicki JC, Egan TD. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2003;26(2):743-7.

14. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998;88(2):305-9.

15. Egan TD, Sharma A, Ashburn MA, Kievit J, Pace NL, Streisand JB. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000;92(3):665-73.

16. Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology 2004;101(3):738-43.

17. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 2004;101(3):729-37.

18. Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn 2001;28(2):155-69.
Figure 1. Mean ± standard error of fentanyl plasma concentration versus time after single doses of 400 µg of Fentanyl Geiser Pharma (test) compared to 400 µg of Actiq (reference) in healthy adult volunteers (n = 36) for the first 48 h (A) and for the rapid absorption phase (B). At 72 h only 1 quantifiable sample was found (subject 05, test formulation, 23.7 pg/ml) and is not represented.
Table I. Pharmacokinetic parameters (mean ± standard deviation) after single doses of 400 µg of Fentanyl Geiser Pharma (test) compared to 400 µg of Actiq (reference) in healthy adult volunteers (n = 36).

|                      | Fentanyl Geiser Pharma (T) | Actiq® (R)   |
|----------------------|----------------------------|--------------|
| $C_{\text{max}}$ (pg/ml) | 814.78 ± 294.96            | 781.83 ± 251.83 |
| $T_{\text{max}}$ (h)* | 0.67 (0.33-2.00)            | 0.83 (0.33-2.00) |
| AUC$_{0-t}$ (pg.h/ml) | 3920.12 ± 1715.00          | 3679.39 ± 1649.49 |
| AUC$_{0-\infty}$ (pg.h/ml) | 4571.30 ± 1903.68         | 4348.80 ± 1900.80 |
| $T_{1/2}$ (h)        | 13.75 ± 8.13               | 13.96 ± 7.35  |

$C_{\text{max}}$: maximum fentanyl concentration. $T_{\text{max}}$: Time when $C_{\text{max}}$ occurs. AUC$_{0-t}$: Area under the curve, calculated from time 0 to the last measured concentration. AUC$_{0-\infty}$: Area under the curve from time 0 extrapolated to infinite time. $T_{1/2}$: half-life.

*Median and range.
Table II. Bioequivalence analysis (Cmax, AUC\textsubscript{0-t}) after single doses of 400 µg of Fentanyl Geiser Pharma (test) compared to 400 µg of Actiq (reference) in healthy adult volunteers (n = 36).

|                      | Fentanyl Geiser Pharma (T) | Actiq\textsuperscript{c} (R) | Geometric mean ratio (T/R) | CI 94.12%      | CI 90%      |
|----------------------|-----------------------------|-----------------------------|----------------------------|----------------|------------|
| Cmax (pg/ml)         | 814.78 ± 294.96             | 781.83 ± 251.83             | 102.85                     | 91.95-115.04   | 93.36-113.31|
| T\textsubscript{max} (h)* | 0.67 (0.33-2.00)            | 0.83 (0.33-2.00)            | -                          | -              | -          |
| AUC\textsubscript{0-t} (pg.h/ml) | 3920.12 ± 1715.00          | 3679.39 ± 1649.49           | 105.53                     | 96.76-115.10   | 97.90-113.76|

Values are mean ± standard deviation.

C\textsubscript{max}: maximum fentanyl concentration; T\textsubscript{max}: Time when C\textsubscript{max} occurs; AUC\textsubscript{0-t}: Area under the curve, calculated from time 0 to the last measured concentration. CI: Confidence Interval.

*Median and range.
Table III. Number of Adverse Events (AE)* after single doses of 400 µg of Fentanyl Geiser Pharma (test) compared to 400 µg of Actiq (reference) in healthy adult volunteers (n = 36).

| AE                  | Fentanyl Geiser Pharma (T) | Actiq® (R) |
|---------------------|-----------------------------|------------|
| Application site excoriation | 2                           | 2          |
| Abdominal disturbance   | 1                           | 0          |
| Nausea/vomiting        | 1                           | 2          |
| Abdominal discomfort   | 1                           | 0          |
| Headache               | 2                           | 0          |
| Muscle contracture     | 0                           | 1          |
| Asymptomatic leukocyturia | 1                          | 0          |
| **TOTAL**             | **8**                       | **5**      |

*All AEs were considered mild.